Search
forProducts matching "alpha 5 reductase inhibitor"
Tracking 11 products like 118 REGROWTH LABS 7HP, 130 UK MADE 1MG FINASTERIDE, 141 Firide 5mg Hair Growth prevent Hair Loss, 141 Firide 5mg Hair Growth prevent Hair Loss and 142 Firide 1mg from by companies like Minoxidil Express, HealthyAreaStore and oasisstad.net. View all 11 products »
Sort by
Research
150-180 / 1000+ resultsresearch Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
research The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research The 5α-Recluctase System and Its Inhibitors
5 alpha-reductase inhibitors, like finasteride, are used to treat conditions like prostate issues and skin disorders.
research Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
research Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
research Synthesis, Biological Evaluation and Molecular Docking of Avicequinone C Analogues as Potential Steroid 5α-Reductase Inhibitors
Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
research Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
research Synthesis and Biological Evaluation of 4-(4-(Alkyl-and Phenylaminocarbonyl)benzoyl)benzoic Acid Derivatives as Non-steroidal Inhibitors of Steroid 5α-Reductase Isozymes 1 and 2
The compound 4c effectively inhibits the enzyme linked to hair loss.
research Macular Abnormalities Associated With 5α-Reductase Inhibitor
Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
research Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research Faculty Opinions recommendation of Association between 5-alpha reductase inhibition and risk of hip fracture.
5-alpha reductase inhibitors do not increase hip fracture risk.
research Influencia del tratamiento con alfa bloqueantes e inhibidores de la 5 alfa reductasa en los hallazgos morfológicos e inmunohistoquímicos de la hiperplasia benigna de próstata
Finasteride treatment makes the prostate look more like a healthy one.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
research Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production
Testosterone's muscle-building effects do not require its conversion to DHT.
research Association of Suicidality and Depression With 5α-Reductase Inhibitors
Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.